Just caught wind of an interesting biotech move that could reshape Esperion's growth trajectory. ESPR announced it's acquiring Corstasis Therapeutics for $75 million upfront, with another $180 million potentially coming through if they hit certain milestones. What's catching my attention is the product they're getting - Enbumyst, which is basically the only FDA-approved nasal spray diuretic for treating fluid buildup in heart failure and liver/kidney disease patients.

So here's why this matters. Esperion already has Nexletol and Nexlizet doing solid work in the cholesterol/cardiovascular space - they saw 38% growth in US sales hitting $115.8 million in the first nine months of last year. But that's mainly targeting cholesterol management. Enbumyst fills a different gap - it's for patients who need diuretic therapy but aren't ready for IV treatment. It's basically a bridge between oral and intravenous options.

The deal makes strategic sense for ESPR because it expands their cardiovascular portfolio beyond just cholesterol drugs. They're targeting a market opportunity over $4 billion in the US alone. The acquisition should close in Q2 2026 - so basically now - and they're funding it through existing credit facilities and by monetizing their Japanese royalties through Athyrium Capital and HealthCare Royalty Partners.

Market reaction was mixed though. ESPR shares dropped 11% when the news hit, and year to date they're down about 21%. Could be profit-taking or investors being cautious about the acquisition costs. But strategically, adding a differentiated diuretic product to their cardiovascular franchise seems like a logical move to accelerate growth beyond just their current oral drug lineup.

The company's Vision 2040 strategy seems to be about building a more robust cardiovascular platform, and this acquisition is definitely a piece of that puzzle. Interesting to see how this plays out once the deal closes.